D

OTTAWA—The Canadian government has promised to match contributions from industry in a new program to increase funding for research. But its procedures have led scientists and industry officials to doubt whether the program, which began April 1, will really stimulate industrial support for universities. The idea seemed simple enough last year when it was first announced: for every dollar provided for eligible university research by the private sector, the federal government would kick in an

Written byDavid Spurgeon
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

The idea seemed simple enough last year when it was first announced: for every dollar provided for eligible university research by the private sector, the federal government would kick in another dollar, up to a maximum of 6 percent of the annual budget for each of the country's three research councils. Science and Technology Minister Frank Oberle said the formula would increase spending by as much as $3.4 billion ($2.5 billion U.S.) the next five years and that it would provide the councils with an unprecedented degree of financial stability.

Under the rules, universities that receive funds from the private sector may apply to the appropriate granting council for matching funds. Projects must contain a valid research component and include a specific goal for the work. The councils will decide which projects are acceptable, as well as the proportion of matching funds to be awarded and their destination—the university that ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies